At the age of ninety years, Dr Eng Meng Tan has had a remarkable impact on the accumulated knowledge of autoimmune diseases, including seminal findings in systemic lupus erythematosus (SLE) and a wide range of other autoimmune diseases. Dating to the first description of the Sm (Smith) autoantibody in SLE, his focus has been the use of autoantibodies as probes to identify and elucidate novel cellular molecules and then translating these discoveries into biomarkers and immunoassays for a wide range of these diseases and, later, cancer. He led efforts to standardize autoantibody nomenclature and testing protocols. Through his mentorship a great number of trainees and collaborators have had remarkably successful careers, and by that virtue he has garnered a remarkable continuing legacy.
KunkelHGTanEM. Autoantibodies and disease. Adv Immunol1964; 4: 351–372.
2.
TanEMKunkelHG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol1966; 96: 464–471.
3.
TanEM. An immunologic precipitin system between soluble nucleoprotein and serum antibody in systemic lupus erythematosus. J Clin Invest1967; 46: 735–745.
4.
TsayGJChanEKLPeeblesCLPollardKMTanEM. An immunoassay differentiating sera with antibodies to Sm alone, antibodies to Sm/RNP complex, and antibodies to RNP alone. Arthritis Rheum1987; 30: 389–396.
5.
TanEMPeeblesC. Quantitation of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination. Am Soc Microbiol1976, pp. 660–664.
6.
ReyesPATanEM. DNA-binding property of Sm nuclear antigen. J Exp Med1977; 145: 749–754.
7.
PollardKMTanEM. Purification of the Sm nuclear autoantigen. Detection and clinical significance of IgM antibody. Clin Exp Immunol1985; 60: 586–596.
8.
TanEMCarrRISchurPHKunkelHG. DNA and antibody to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest1966; 45: 1732–1740.
9.
TanEMNataliPG. Comparative study of antibodies to native and denatured DNA. J Immunol1970; 104: 902–906.
10.
TanEM. Antibodies to deoxyribonucleic acid irradiated with ultraviolet light: detection by precipitins and immunofluorescence. Science1968; 161: 1353–1354.
RobitaillePTanEM. Relationship between deoxyribonucleoprotein and deoxyribonucleic acid antibodies in systemic lupus erythematosus. J Clin Invest1973; 52: 316–323.
13.
TanEMStoughtonRB. Ultraviolet light-induced damage to deoxyribonucleic acid in human skin. J Invest Dermatol1969; 52: 537–542.
14.
IkebeKGuptaCTanEM. Characterization of DNA in poly-ethylene glycol precipitated immune complexes from sera of patients with systemic lupus erythematosus. Clin Exp Immunol1983; 53: 169–177.
15.
ReimerGRubinRLKotzinBLTanEM. Anti-native DNA antibodies from autoimmune sera also bind to DNA in mitochondria. J Immunol1984; 133: 2532–2536.
SharpGCIrvinWTanEMGouldGHolmanHR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med1972; 52: 148–159.
AlspaughMATanEM. Antibodies to cellular antigens in Sjogren's syndrome. J Clin Invest1975; 55: 1067–1073.
20.
AlspaughMATalalNTanEM. Differentiation and characterization of autoantibodies and their antigens in Sjogren's syndrome. Arthritis Rheum1976; 19: 216–222.
21.
ChanEKLTanEM. Human autoantibody-reactive epitopes of SS-B/La are highly conserved in comparison with epitopes recognized by murine monoclonal antibodies. J Exp Med1987; 166: 1627–1640.
22.
ChanEKLTanEM. The small nuclear ribonucleoprotein SS-B/La binds RNA with a conserved protease-resistant domain of 28 kilodaltons. Mol Cell Biol1987; 7: 2588–2591.
23.
Ben-ChetritEGandyBJTanEMSullivanKF. Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J Clin Invest1989; 83: 1284–1292.
24.
Ben-ChetritEChanEKLSullivanKFTanEM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med1988; 167: 1560–1571.
25.
ChanEKLSullivanKFTanEM. Ribonucleoprotein SS-B/La belongs to a protein family with consensus sequences for RNA-binding. Nucleic Acid Res1989; 17: 2233–2244.
26.
BuyonJPBen-ChetritEKarpS. Acquired congenital heart block: pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus. J Clin Invest1989; 84: 627–634.
27.
ChanEKLSullivanKFFoxRITanEM. Sjögren's syndrome nuclear antigen B (La): cDNA cloning, structural domains, and autoepitopes. J Autoimmun1989; 2: 321–327.
28.
ChanEKLFrancoeurA-MTanEM. Epitopes, structural domains, and asymmetry of amino acid residues in SS-B/La nuclear protein. J Immunol1986; 136: 3744–3749.
29.
Ben-ChetritEFoxRITanEM. Dissociation of immune responses to the SS-A(Ro) and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's Syndrome. Arthritis Rheum1990; 33: 349–355.
30.
HarmonCEDengJSPeeblesCLTanEM. The importance of tissue substrate in the SS-ARo antigen–antibody system. Arthritis Rheum1984; 27: 166–173.
31.
ReddyRHenningDTanEMBuschH. Identification of a La protein binding site in a RNA polymerase III transcript (4.51 RNA). J Biol Chem1983; 258: 8352–8356.
32.
ChanEKLTanEMWardDCMateraAG. Human 60-kD SS-A/Ro ribonucleoprotein autoantigen gene (SSA2) localized to 1q31 by fluorescence in situ hybridization. Genomics1994; 23: 298–300.
33.
AlspaughMSTanEM. Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence. Arthritis Rheum1976; 19: 711–719.
34.
TanEM. The possible role of Epstein–Barr virus in rheumatoid arthritis. Rev Infect Dis1979; 1: 997–1005.
35.
AitchesonCTPeeblesCJoslinFTanEM. Characteristics of antinuclear antibodies in rheumatoid arthritis. Arthritis Rheum1980; 1980: 528–538.
36.
WilsonMRArroyaveCMMilesLTanEM. Immune reactants in cryoproteins. Ann Rheum Dis1977; 36: 540–548.
37.
ArroyaveCMWilsonMRTanEM. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus. J Immunol1976; 116: 821–826.
38.
WilsonMRArroyaveCMNakamuraRMVaughanJHTanEM. Activation of the alternative complement pathway in systemic lupus erythematosus. Clin Exp Immunol1976; 26: 11–20.
39.
KanayamaYPeeblesCTanEMCurdJG. Complement-activating abilities of defined antinuclear antibodies. Arthritis Rheum1986; 29: 748–754.
40.
ArroyaveCMTanEM. Detection of complement activation by counterimmunoelectrophoresis. J Immunol Methods1976; 13: 101–112.
41.
GuptaRCTanEM. Isolation of circulating immune complexes by conglutinin and separation of antigen from dissociated complexes by immobilized protein A. Clin Exp Immunol1981; 46: 9–19.
42.
RingJSenterTCornellRCArroyaveCMTanEM. Complement and immunoglobulin deposits in the skin of patients with atopic dermatitis. Br J Dermatol1978; 99: 495–501.
43.
RingJFritzlerMJArroyaveCMTanEM. In vitro histamine and serotonin release and independent release reaction and changes of human blood cells. Clin Exp Immunol1978; 32: 105–108.
44.
FritzlerMJRingJArroyaveCMTanEM. Human blood cells: ultrastructural changes and mediator release after exposure to radiographi contrast media. Can Med Assoc J1978; 119: 901–906.
45.
RingJSenterTCornellRCArroyaveCMTanEM. Plasma complement and histamine changes in atopic dermatitis. Br J Dermatol1979; 100: 521–530.
46.
ArroyaveCMStevensonDDVaughanJHTanEM. Plasma complement changes during bronchospasm provoked in asthmatic patients. Clin Allergy1977; 7: 173–182.
47.
DouvasASAchtenMTanEM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem1979; 254: 10514–10522.
48.
MiyachiKTanEM. Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases. Arthritis Rheum1979; 22: 87–93.
49.
FrancoeurAMPeeblesCLHeckmanKJLeeJCTanEM. Identification of ribosomal protein autoantigens. J Immunol1985; 135: 2478–2384.
50.
MannsMPJohnsonEFGriffinKJTanEMSullivanKF. Major anitgen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis if cytochrome P450db1. J Clin Invest1989; 83: 1066–1072.
51.
BernsteinRMSteigerwaldJCTanEM. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol1982; 48: 43–51.
52.
ReddyRTanEMHenningDNohgaKBuschH. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem1983; 258: 1383–1386.
53.
LischweMAOchsRLReddyR. Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34 000;pI,8.5) rich in NG,NG-dimethylarginine. J Biol Chem1985; 260: 14304–14310.
54.
ReichlinMMaddisonPJTargoffI. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol1984; 4: 40–47.
55.
PollardKMReimerGTanEM. Autoantibodies in scleroderma. Clin Exp Rheumatol1989; 7: S57–S62.
56.
ReimerGScheerUPetersJMTanEM. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes. J Immunol1986; 137: 3802–3808.
57.
ReimerGRaskaITanEMScheerU. Human autoantibodies: probes for nucleolus structure and function. Virchows Arch B1987; 54: 131–143.
58.
ReimerGSteenVDPenningCAMedsgerTATanEM. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum1988; 31: 525–532.
59.
ReimerGPollardKMPenningCA. Monoclonal autoantibody from a (New Zealand black×New Zealand white) F1 mouse and some human scleroderma sera target and Mr 34 000 nucleolar protein of the U3 RNP particle. Arthritis Rheum1987; 30: 793–800.
60.
ReimerGRoseKMScheerUTanEM. Autoantibody to RNA polymerase 1 in scleroderma sera. J Clin Invest1987; 79: 65–72.
61.
ReimerGRaskaIScheerUTanEM. Immunolocalization of 7-2-ribonucleoprotein in the granular component of the nucleolus. Exp Cell Res1988; 176: 117–128.
62.
AlderuccioFChanEKLTanEM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolus complex. J Exp Med1991; 173: 941–952.
63.
ChanEKLImaiHHamelJCTanEM. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolar organizer region auotantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J Exp Med1991; 174: 1239–1244.
64.
ImaiHChanEKLPeeblesCL. Analysis of autoantibody to the nucleolus organizer region antigen NOR-90 in 13 patients. Arthritis Rheum1992; 35: S171.
65.
ImaiHOchsRLKiyosawaK. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol1992; 140: 859–870.
66.
ImaiHFritzlerMJNeriR. Immunocytochemical localization of two Mr forms of human NOR-90 (Upstream Binding Factor) and associated antigens reactive with autoimmune sera. Mol Biol Rep1994; 19: 115–124.
67.
TurleySJTanEMPollardKM. Molecular cloning and sequence analysis of U3 snRNA-associated mouse fibrillarin. Biochim Biophys Acta1993; 1216: 119–122.
68.
TakeuchiKTurleySJTanEMPollardKM. Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity. J Immunol1995; 154: 961–971.
OchsRLSteinTWChanEKLRuutuMTanEM. cDNA cloning and characterization of a novel nucleolar protein. Mol Biol Cell1996; 7: 1015–1024.
71.
PollardKMLeeDKCasianoCA. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J Immunol1997; 158: 3521–3528.
72.
BuyonJPSladeSGChanEKLTanEMWinchesterR. Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis. J Immunol Methods1990; 129: 207–210.
73.
ChanEKLHamelJCBuyonJPTanEM. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest1991; 87: 68–76.
74.
MiyachiKFritzlerMJTanEM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol1978; 121: 2228–2234.
75.
OgataKKurkiPCelisJENakamuraRMTanEM. Monoclonal antibodies to a nuclear protein (PCNA/Cyclin) associated with DNA replication. Exp Cell Res1987; 168: 475–486.
76.
ZuberMTanEMMasaruR. Involvement of proliferating cell nuclear antigen (cyclin) in DNA replication in living cells. Mol Cell Biol1989; 9: 57–66.
77.
WongRLKatzMEOgataKTanEMCohenS. Inhibition of nuclear DNA synthesis by an autoantibody to proliferating cell nuclear antigen/cyclin. Cell Immunol1987; 110: 443–448.
78.
OgataKOgataYTakasakiYTanEM. Epitopes on proliferating cell nuclear antigen recognized by human lupus autoantibody and murine monoclonal antibody. J Immunol1987; 139: 2942–2946.
79.
TakasakiYFishwildDTanEM. Characterization of proliferating cell nuclear antigen recognized by autoantibodies in lupus sera. J Exp Med1984; 159: 981–992.
80.
TakasakiYDengJ-STanEM. A nuclear antigen associated with cell proliferation and blast transformation. J Exp Med1981; 154: 1899–1909.
81.
OgataKOgataYNakamuraRMTanEM. Purification and n-terminal amino acid sequence of proliferating cell nuclear antigen (PCNA)/CYCLIN and development of ELISA for anti-PCNA antibodies. J Immunol1985; 135: 2623–2627.
82.
LandbergGTanEMRoosG. Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and ki-67 antigen: a new view of the cell cycle. Exp Cell Res1990; 187: 111–118.
83.
TanC-KSullivanKLiX. Autoantibody to the proliferating cell nuclear antigen neutralizes the activity of the auxilary protein for DNA polymerase delta. Nucleic Acid Res1987; 15: 9299–9308.
84.
KurkiPLotzMOgataKTanEM. Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes. J Immunol1987; 138: 4114–4120.
85.
TakasakiYRobinsonWTanEM. Proliferating cell nuclear antigen in blast crisis cells of patients with chronic myeloid leukemia. J Nat Cancer Inst1984; 73: 655–661.
86.
HuffJPRoosGPeeblesCL. Insights into native epitopes of proliferating cell nuclear antigen using recombinant DNA protein products. J Exp Med1990; 172: 419–429.
87.
RoosGLandbergGSullivanKFTanEM. Analysis of PCNA (proliferating cell nuclear antigen) in the cell cycle and application to flow cytometry. SPIE1989; 1063: 144–149.
88.
RoosGLandbergGHuffJP. Analysis of the epitopes of proliferating cell nuclear antigen recognized by monoclonal antibodies. Lab Invest1993; 68: 204–210.
RubinRLJoslinFGTanEM. A solid-phase radioimmunoassay for anti-histone antibodies in human sera: comparison with an immunofluorescence assay. Scand J Immunol1982; 15: 63–70.
95.
PortanovaJPArndtRETanEMKotzinBL. Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions. J Immunol1987; 138: 446–451.
SuzukiTBurlingameRWCavalotF. Antibodies in rabbits immunized with cationized IgG react with histones H3 and H4. Arthritis Rheum1992; 35: 1218–1226.
98.
RubinRLMcNallyEMNusinowSRRobinsonCATanEM. IgG antibodies to the histone comples H2A–H2B characterize procainamide-induced lupus. Clin Immunol Immunopathol1985; 36: 49–59.
99.
PortanovaJPRubinRLJoslinFGAgnelloVDTanEM. Reactivity of anti-histone antibodies induced by procainamide and hydralazine. Clin Immunol Immunopathol1982; 25: 67–79.
100.
TotoritisMCTanEMMcNallyEMRubinRL. Association of antibody to histone complex H2A–H2B with symptomatic procainamide-induced lupus. N Engl J Med1988; 318: 1431–1462.
101.
RubinRLNusinowSRJohnsonAD. Serologic changes during induction of lupus-like disease by procainamide. Am J Med1986; 80: 999–1002.
102.
RubinRLJoslinFGTanEM. Specificity of anti-histone antibodies in systemic lupus erythematosus. Arthritis Rheum1982; 25: 779–782.
103.
FurutaKChanEKLKiyosawaK. Heterochromatin protein HP1Hsβ (p25β) and its localization with centromeres in mitosis. Chromosoma1997; 106: 11–19.
104.
FurutaKHildebrandtBMatsuokaS. Immunological characterization of heterochromatin protein p25β autoantibodies and relationship with centromere autoantibodies and pulmonary fibrosis in systemic scleroderma. J Mol Med1998; 76: 54–60.
105.
DengJSElenitsasRTanEM. Anti-nuclear matrix (NM ab): hidden antinuclear antibody in patients with connective tissue diseases (CTD). Fed Proc1989; 90: 553.
106.
FritzlerMJAliRTanEM. Antibodies from patients with mixed connective tissue disease react with heterogeneous nuclear ribonucleoprotein or ribonucleic acid (hnRNP-RNA) of the nuclear matrix. J Immunol1984; 132: 1216–1222.
107.
HassfeldWChanEKLMathisonDA. Molecular definition of heterogeneous nuclear ribonucleoprotein R (hnRNP R) using autoimmune antibody: immunological relationship with hnRNP P. Nucleic Acid Res1998; 26: 439–445.
108.
MoroiYPeeblesCFritzlerMJSteigerwaldJTanEM. Autoantibody to centromere (Kinetochore) in scleroderma sera. Proc Nat Acad Sci USA1980; 77: 1627–1631.
109.
TanEMRodnanGPGarciaI. Diversity of antinuclear antibodies in progressive systemic sclerosis: Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum1980; 23: 617–625.
110.
MoroiYHartmanALNakanePKTanEM. Distribution of kinetochore (centromere) antigen in mammalian cell nuclei. J Cell Biol1981; 90: 254–259.
111.
PressRIPeeblesCLKumagaiYOchsRLTanEM. Antinuclear antibodies in patients with silicone breast implants. Lancet1992; 340: 1304–1307.
112.
TanEM. Antinuclear antibodies in scleroderma. Int J Dermatol1981; 20: 569–573.
113.
MiyachiKGuptaRCDicksonERTanEM. Precipitating antibodies to mitochondrial antigens in patients with primary biliary cirrhosis. Clin Exp Immunol1980; 39: 599–606.
114.
RaskaLOchsRLAndradeLEC. Association between the nucleolus and the coiled body. J Struct Biol1990; 104: 120–127.
115.
AndradeLEChanEKLRaskaI. Human autoantibody to a novel protein of the nuclear coiled body immunological characteristics and cDNA cloning of p80-coilin. J Exp Med1991; 173: 1407–1419.
116.
RaskaIAndradeLECOchsRL. Immunological and ultrastructural studies of the nuclear coiled body with autoimmune antibodies. Exp Cell Res1991; 195: 27–37.
117.
AndradeLETanEMChanEKL. Immunocytochemical analysis of the coiled body in the cell cycle and during cell proliferation. Proc Nat Acad Sci USA1993; 90: 1947–1951.
118.
OchsRLSteinTWJrTanEM. Coiled bodies in the nucleolus of breast cancer cells. J Cell Sci1994; 107: 385–399.
119.
TanEM. Autoantibodies to nuclear lamins. Ann Intern Med1988; 108: 897–898.
120.
PollardKMChanEKLGrantBJ. In vitro posttranslational modification of lamin B cloned from a human T-cell line. Mol Cell Biol1990; 10: 2164–2175.
121.
KonstantinovKVon MikeczABuchwaldD. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J Clin Invest1996; 98: 1888–1896.
CasianoCALandbergGOchsRLTanEM. Autoantibodies to a novel cell cycle-regulated protein which accumulates in the nuclear matrix during S phase and localizes to kinetochores and spindle midzone during mitosis. J Cell Sci1993; 106: 1045–1056.
124.
CasianoCAHumbelRLPeeblesCCoviniGTanEM. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmunity1995; 8: 575–586.
125.
BáezATorresKTanEMPommierYCasianoCA. Expression of proliferation-associated nuclear autoantigens, p330d/CENP-F and PCNA, in differentiation and in drug-induced growth inhibition using two-parameter flow cytometry. Cell Prolif1996; 29: 183–196.
126.
LandbergGErlansonMRoosGTanEMCasianoCA. Nuclear autoantigen p330d/CENP-F: A marker for cell proliferation in human malignancies. Cytometry1996; 25: 90–98.
127.
RattnerJBReesJWhiteheadCM. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med1997; 20: 308–319.
128.
ErlansonMCasianoCATanEM. Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Modern Pathol1999; 12: 69–74.
129.
LandbergGTanEM. Characterization of a DNA-binding nuclear autoantigen mainly associated with S phase and G2 cells. Exp Cell Res1994; 212: 255–261.
130.
ThomasPJKaurJSAitchesonCTRobinsonWATanEM. Antinuclear, antinucleolar, and anticytoplasmic antibodies in patients with malignant melanoma. Cancer Res1983; 43: 1372–1380.
131.
ImaiHNakanoYKiyosawaKTanEM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer1993; 71: 26–35.
132.
ImaiHKiyosawaKChanEKLTanEM. Autoantibodies in viral hepatitis-related hepatocellular carcinoma. Intervirology1993; 35: 73–85.
133.
ImaiHChanEKLKiyosawaKFuXDTanEM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest1993; 92: 2419–2426.
134.
ImaiHFurutaKLandbergG. Autoantibody to DNA topoisomerase II in primary liver cancer. Clin Cancer Res1995; 1: 417–424.
135.
CoviniGVon MühlenCAPacchettiS. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol1997; 26: 1255–1265.
136.
ZhangJYChanEKLPengXXTanEM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med1999; 189: 1101–1110.
137.
TanEMShiFD. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol2003; 134: 169–177.
138.
KoziolJAZhangJYCasianoCA. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res2003; 9: 5120–5126.
139.
ShiFDZhangJYLiuD. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate2005; 63: 252–258.
140.
ZhangJYMegliorinoRPengXX. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol2007; 46: 107–114. .
141.
TanEMZhangJ. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev2008; 222: 328–340.
142.
LooiKSNakayasuESDiazRA. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res2008; 7: 4004–4012.
143.
ZhangJYTanEM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn2010; 10: 321–328.
144.
TanEM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest2001; 108: 1411–1415.
145.
LuMNakamuraRMDentED. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol2001; 159: 945–953.
146.
ZhangJYChanEKLPengXX. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol2001; 100: 149–156.
147.
RomWNGoldbergJDAddrizzo-HarrisD. Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer2010; 10: 234.
148.
ChenYZhouYQiuS. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett2010; 289: 32–39.
149.
ZhangJYLooiKSTanEM. Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer. Method Mol Biol2009; 520: 1–10.
TanEMZhangJ. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev2008; 222: 328–340.
152.
DaiLRenPLiuM. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. Clin Immunol2014; 152: 127–139.
153.
MuroYChanEKLLandbergGTanEM. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Commun1995; 207: 1029–1037.
154.
ZhuWGChanEKLLiJHemmerichPTanEM. Transcription activating property of autoantigen SG2NA and modulating effect of WD-40 repeats. Exp Cell Res2001; 269: 312–321.
155.
YamanakaHWillisEHPenningCA. Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. J Clin Invest1987; 80: 900–904.
156.
Von MühlenCAChanEKLPeeblesCL. Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases. Clin Exp Immunol1995; 100: 67–74.
157.
OchsRLSteinTWJrPeeblesCLGittesRFTanEM. Autoantibodies in interstitial cystitis. J Urol1994; 151: 587–592.
158.
OchsRLMuroYSiYZ. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol2000; 105: 1211–1220.
159.
AndradeLECChanEKLPeeblesCLTanEM. Two major autoantigen–antibody systems of the mitotic spindle apparatus. Arthritis Rheum1996; 39: 1643–1653.
160.
LuYYePChenSLTanEMChanEKL. Identification of kinectin as a novel Behcet's disease autoantigen. Arthritis Res Ther2005; 7: R1133–R1139.
161.
CasianoCAMartinSJGreenDRTanEM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med1996; 184: 765–770.
162.
CasianoCAOchsRLTanEM. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ1998; 5: 183–190.
163.
PollardKMPearsonDLBlüthnerMTanEM. Proteolytic cleavage of a self-antigen following xenobiotic-induced cell death produces a fragment with novel immunogenic properties. J Immunol2000; 165: 2263–2270.
164.
TanEMKunkelHG. An immunofluorescent study of the skin lesions in systemic lupus erythematosus. Arthritis Rheum1966; 9: 37–46.
165.
TanEM. Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus. J Lab Clin Med1967; 70: 800–812.
166.
AlspaughMMaddisonP. Resolution of the identity of certain antigen–antibody systems in systemic lupus erythematosus and sjogren's syndrome: an interlaboratory collaboration. Arthritis Rheum1979; 22: 796–798.
167.
MahlerMMiyachiKPeeblesCFritzlerMJ. The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmun Rev2012; 11: 771–775.
168.
SheroJHBordwellBRothfieldNFEarnshawWC. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science1986; 231: 737–740.
169.
GuldnerHHSzosteckiCVosbergHP. Scl-70 autoantibodies from scleroderma patients recognize a 95KD protein identified as DNA topoisomerase I. Chromosoma1986; 94: 132–138.
170.
MaulGGFrenchBTVan VenrooijWJJimenezSA. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Nat Acad Sci USA1986; 83: 5145–5149.
171.
FritzlerMJRattnerJBLuftLM. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev2010; 10: 194–200.
172.
NakamuraRMTanEM. Recent progress in the study of autoantibodies to nuclear antigens. Human Pathol1977; 9: 85–91.
173.
NakamuraRMPeeblesCLMoldenDPTanEM. Advances in laboratory tests for autoantibodies to nuclear antigens in systemic rheumatic diseases. Lab Med1984; 15: 190–198.
174.
NakamuraRMTanEM. Recent advances in laboratory tests and the significance of autoantibodies to nuclear antigens in systemic rheumatic diseases. Clin Lab Med1986; 6: 41–53.
175.
MoldenDPNakamuraRMTanEM. Standardization of the immunofluorescence test for autoantibody to nuclear antigens (ANA): use of reference sera of defined antibody specificity. Am J Clin Pathol1984; 82: 57–66.
176.
TanEMFritzlerMJMcDougalJS. Reference sera for antinuclear antibodies I. Antibodies to native DNA, Sm, nuclear RNP, and SS-B/La. Arthritis Rheum1982; 25: 1003–1005.
177.
SmolenJSSteinerGTanEM. Standards of care: the value and importance of standardization. Arthritis Rheum1997; 40: 410–412.
178.
SmolenJSButcherBFritzlerMJ. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and Western immunoblotting. Arthritis Rheum1997; 40: 413–418.
179.
TanEMFeltkampTEWSmolenJS. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum1997; 40: 1601–1611.
180.
TanEMSmolenJMcDougalJS. A critical evaluation of enzyme immunoassays for the detection of antinuclear antibodies of defined specificities. I. Precision, sensitivity and specificity. Arthritis Rheum1999; 42: 455–464.
181.
TanEMSmolenJSMcDougalJS. A critical evaluation of enzyme immunoassay kits for the detection of antinuclear antibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol2002; 29: 68–74.
182.
FritzlerMJWiikATanEM. A critical evaluation of enzyme immunoassay kits for detection of antinuclear antibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol2003; 30: 2374–2381.
183.
ChanEKDamoiseauxJCarballoOG. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. Front Immunol2015; 6: 412.
184.
ChanEKDamoiseauxJde MeloCW. Report on the Second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus2016; 25: 797–804.
185.
DamoiseauxJvon MuhlenCAGarcia-de la TorreI. International Consensus on ANA Patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights2016; 7: 1, .
186.
ConradKAndradeLEChanEK. From autoantibody research to standardized diagnostic assays in the management of human diseases—report of the 12th Dresden Symposium on Autoantibodies. Lupus2016; 25: 787–796.
187.
PinnasJNorthwayJDTanEM. Antinucleolar antibodies in human sera. J Immunol1973; 111: 996–1004.
188.
NotmanDDKurataNTanEM. Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med1975; 83: 464–469.
189.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
190.
TanEM. Autoantibodies to nuclear antigens. Adv Immunol1982; 33: 167–240.
191.
TanEM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol1989; 44: 93–151.
192.
TanEMChanEKLSullivanKFRubinRL. Antinuclear antibodies (ANAs): diagnositically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol1988; 47: 121–141.
193.
TanEM. Interactions between autoimmunity and molecular and cell biology. Bridges between clinical and basic sciences. J Clin Invest1989; 84: 1–6.
194.
TanEMChanEKL. Molecular biology of autoantigens and new insights into autoimmunity. Clin Investig1993; 71: 327–330.
195.
von MuhlenCATanEM. Autoantibodies in the diagnosis of systemic rheumatic disease. Semin Arthritis Rheum1995; 24: 323–358.
